Q-omics provides the consensus-scored LYST-AS1 profile across patient tissues and cancer cell-line models. LYST-AS1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, LYST-AS1 is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, LYST-AS1 RNA expression shows 13,852 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight HNSC, KIRC, and DLBC as cancer lineages where LYST-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LYST-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LYST-AS1 survival associations across molecular data types. LYST-AS1 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LYST-AS1 RNA expression–survival associations across cancer types. High LYST-AS1 expression shows unfavorable associations in LUSC, KICH and UVM, but favorable associations in HNSC, LAML and STAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify HNSC as the clearest survival context for LYST-AS1 RNA expression.
This table summarizes LYST-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LYST-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LYST-AS1 shows lower tumor expression in THCA and higher tumor expression in KIRC, HNSC and KIRP. The KIRC box plot shows higher LYST-AS1 RNA expression in tumor versus normal tissue (log2 FC = +0.115, t-test p < 0.001).
This table shows molecular features associated with LYST-AS1 in patient tissues and cancer cell lines. In patient samples, LYST-AS1 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
